Immune Checkpoint Inhibitors (ICI) have shifted the paradigm of cancer therapy treatment. Despite their efficacy, ICIs occasionally induce immune-related adverse events (irAE), which can affect various organs, namely the liver. The aim of this study is to perform a comprehensive clinical description of the hepatic irAEs associated with ICI in a population of a tertiary hospital centre.